MYCN and neuroblastoma: DpC treatment significantly decreased MYC protein levels across all neuroblastoma cell lines, which suggests promising new therapy strategies, especially in MYCN-amplified neuroblastomas, which account for approximately 20% of cases and rank among those with the most difficult course of the disease [1].